Pepto-Bismol Dosage for Diarrhea
For adults and children 12 years and older with diarrhea, take 30 mL (525 mg bismuth subsalicylate) every 30 minutes or 60 mL every hour as needed, not exceeding 8 doses (240 mL total) in 24 hours, and do not use for more than 2 days. 1
Adult and Adolescent Dosing (≥12 years)
- Standard dose: 30 mL (one dose cup) every 30 minutes OR 60 mL (two doses) every hour as needed for diarrhea 1
- Maximum daily dose: 240 mL (8 doses) in 24 hours 1
- Duration limit: Continue until diarrhea stops but do not exceed 2 days of use 1
- Each 30 mL dose contains: 525 mg bismuth subsalicylate 1
- Important: Shake well before use and only use the dose cup provided 1
Pediatric Dosing (Under 12 years)
- Children under 12 years: Ask a doctor before use 1
- Research supports dosing of 20 mg/kg five times daily for children aged 4-28 months in clinical studies, though this is not reflected in current FDA labeling 2
- Studies have used 100-150 mg/kg/day divided into multiple doses for children 4-36 months old, but concerns about Reye syndrome limit routine pediatric recommendations 3, 4, 5
Hydration Requirements
- Drink plenty of clear fluids to help prevent dehydration caused by diarrhea 1
- Maintain adequate fluid intake guided by thirst, prioritizing glucose-containing beverages or electrolyte-rich soups 6
When Pepto-Bismol May NOT Be the Best Choice
Loperamide is actually the preferred first-line agent for acute diarrhea in adults based on current gastroenterology guidelines, with an initial dose of 4 mg followed by 2 mg after each loose stool (maximum 16 mg daily) 7, 6. Comparative studies show loperamide provides faster and more effective relief than bismuth subsalicylate at standard nonprescription doses 8.
However, bismuth subsalicylate remains a reasonable option, particularly for:
- Travelers' diarrhea prevention and treatment 9, 10
- Patients who prefer to avoid opioid-based antidiarrheals 10
- Mild to moderate diarrhea without high fever or dysentery 9
Clinical Efficacy Evidence
- Meta-analysis shows bismuth subsalicylate provides 3.7 times greater odds of diarrhea relief compared to placebo (95% CI 2.1-6.3) 10
- Treatment reduces stool frequency, improves consistency, and shortens disease duration in clinical trials 2, 4
- For travelers' diarrhea prevention, bismuth subsalicylate provides 3.5 times greater odds of prevention compared to placebo when taken for up to 21 days 10
Critical Safety Considerations
- Reye syndrome risk: Theoretical concern in children with viral illnesses due to salicylate content, which is why medical consultation is required for children under 12 5
- Higher adverse event rate: Bismuth subsalicylate has a higher rate of adverse events compared to other antidiarrheal treatments 11
- Blood bismuth and salicylate levels remain well below toxic concentrations at recommended doses 2, 4